References
- Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979;301(2):61–68. https://doi.org/10.1056/NEJM197907123010201. PMID: 449946.
- Bertrand ME, Legrand V, Boland J, Fleck E, Bonnier J, Emmanuelson H, Vrolix M, Missault L, Chierchia S, Casaccia M, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation 1998;98(16):1597–1603. https://doi.org/10.1161/01.cir.98.16.1597. PMID: 9778323.
- Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent anticoagulation restenosis study investigators. N Engl J Med 1998;339(23):1665–1671. https://doi.org/10.1056/NEJM199812033392303. PMID: 9834303.
- Smith SC Jr., Feldman TE, Hirshfeld JW Jr., Jacobs AK, Kern MJ, King SB 3rd, Morrison DA, O’Neill WW, Schaff HV, Whitlow PL, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American college of cardiology/American heart association task force on practice guidelines (ACC/AHA/SCAI writing committee to update the 2001 guidelines for percutaneous coronary Intervention). J Am Coll Cardiol 2006;47(1):e1–121. https://doi.org/10.1016/j.jacc.2005.12.001. PMID: 16386656.
- Cook S, Windecker S. Early stent thrombosis: past, present, and future. Circulation 2009;119(5):657–659. https://doi.org/10.1161/CIRCULATIONAHA.108.842757. PMID: 19204315.
- Park DW, Park SW, Park KH, Lee BK, Kim YH, Lee CW, Hong MK, Kim JJ, Park SJ. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 2006;98(3):352–356. https://doi.org/10.1016/j.amjcard.2006.02.039. PMID: 16860022.
- Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358(9281):527–533. https://doi.org/10.1016/s0140-6736(01)05701-4. PMID: 11520521.
- Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288(19):2411–2420. https://doi.org/10.1001/jama.288.19.2411. PMID: 12435254.
- Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American college of cardiology foundation/American heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. Circulation 2011;124(23):e574–651. https://doi.org/10.1161/CIR.0b013e31823ba622. PMID: 22064601.
- Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, Ohya M, Suwa S, Takagi K, Nanasato M, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA 2019;321(24):2414–2427. https://doi.org/10.1001/jama.2019.8145. PMID: 31237644.
- Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, Cha JY, Collier T, Dangas G, Dudek D, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med 2019;381(21):2032–2042. https://doi.org/10.1056/NEJMoa1908419. PMID: 31556978.
- De Luca G, Damen SA, Camaro C, Benit E, Verdoia M, Rasoul S, Liew HB, Polad J, Ahmad WA, Zambahari R, et al. Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial). EuroIntervention 2019;15(11):e990–e998. https://doi.org/10.4244/EIJ-D-19-00539. PMID: 31422929.
- Thim T, Johansen MB, Chisholm GE, Schmidt M, Kaltoft A, Sorensen HT, Thuesen L, Kristensen SD, Botker HE, Krusell LR, et al. Clopidogrel discontinuation within the first year after coronary drug-eluting stent implantation: an observational study. BMC Cardiovasc Disord 2014;14(1):100. https://doi.org/10.1186/1471-2261-14-100. PMID: 25125079.
- Konishi A, Ho M, Shirai Y, Shirato H. first approval of improved medical device conditional on use-result survey in Japan- regulatory review of polymer-free drug-coated biofreedom coronary stent. Circulation J 2018;82(6):1487–1490. https://doi.org/10.1253/circj.CJ-17-1425. PMID: 29563353.
- Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ (Clinical Research Ed) 2011;343:d5928. https://doi.org/10.1136/bmj.d5928. PMID: 22008217.
- Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical Research Ed) 2008;336:924–926. https://doi.org/10.1136/bmj.39489.470347.AD. PMID: 18436948.
- Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700. https://doi.org/10.1136/bmj.b2700. PMID: 19622552.
- Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding academic research consortium. Circulation 2011;123(23):2736–2747. https://doi.org/10.1161/CIRCULATIONAHA.110.009449. PMID: 21670242.
- Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, Choi D, Kang TS, Park BE, Kang WC, et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal safety and efficacy of 3-month dual antiplatelet Therapy following endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 2012;60(15):1340–1348. https://doi.org/10.1016/j.jacc.2012.06.043. PMID: 22999717.
- Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, King SB 3rd, Negoita M, Liu M, de Paula JE, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. Jama 2013;310(23):2510–2522. https://doi.org/10.1001/jama.2013.282183. PMID: 24177257.
- Vranckx P, Valgimigli M, Juni P, Hamm C, Steg PG, Heg D, van Es GA, McFadden EP, Onuma Y, van Meijeren C, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet (London, England) 2018;392(10151):940–949. https://doi.org/10.1016/S0140-6736(18)31858-0. PMID: 30166073.
- Hahn JY, Song YB, Oh JH, Chun WJ, Park YH, Jang WJ, Im ES, Jeong JO, Cho BR, Oh SK, et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. Jama 2019;321(24):2428–2437. https://doi.org/10.1001/jama.2019.8146. PMID: 31237645.
- Mehta SR, Bainey KR, Cantor WJ, Lordkipanidze M, Marquis-Gravel G, Robinson SD, Sibbald M, So DY, Wong GC, Abunassar JG, et al. 2018 Canadian cardiovascular society/Canadian association of interventional cardiology focused update of the guidelines for the use of antiplatelet therapy. Can J Cardiol 2018;34(3):214–233. https://doi.org/10.1016/j.cjca.2017.12.012. PMID: 29475527.
- Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Juni P, Kastrati A, Kolh P, Mauri L, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European society of cardiology (ESC) and of the European association for cardio-thoracic surgery (EACTS). Eur Heart J 2018;39(3):213–260. https://doi.org/10.1093/eurheartj/ehx419. PMID: 28886622.
- Nayak AK, Kawamura A, Nesto RW, Davis G, Jarbeau J, CT P, Gossman DE, Piemonte TC, Riskalla N, Chauhan MS. Myocardial infarction as a presentation of clinical in-stent restenosis. Circulation J 2006;70(8):1026–1029. https://doi.org/10.1253/circj.70.1026. PMID: 16864936.
- Otsuka F, Byrne RA, Yahagi K, Mori H, Ladich E, Fowler DR, Kutys R, Xhepa E, Kastrati A, Virmani R, et al. Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. Eur Heart J 2015;36(32):2147–2159. https://doi.org/10.1093/eurheartj/ehv205. PMID: 25994755.
- Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrie D, Naber C, Lipiecki J, Richardt G, Iniguez A, Brunel P, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med 2015;373(21):2038–2047. https://doi.org/10.1056/NEJMoa1503943. PMID: 26466021.
- Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361(11):1045–1057. https://doi.org/10.1056/NEJMoa0904327. PMID: 19717846.
- Bundhun PK, Huang F. Post percutaneous coronary interventional adverse cardiovascular outcomes and bleeding events observed with prasugrel versus clopidogrel: direct comparison through a meta-analysis. BMC Cardiovasc Disord 2018;18(1):78. https://doi.org/10.1186/s12872-018-0820-6. PMID: 29720092.
- Basaraba JE, Barry AR. Short- versus standard-term dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation: A meta-analysis. J Cardiol 2017;69(1):353–358. https://doi.org/10.1016/j.jjcc.2016.07.021. PMID: 27590413.
- Verdoia M, Kedhi E, Ceccon C, Suryapranata H, De Luca G. Duration of dual antiplatelet therapy and outcome in patients with acute coronary syndrome undergoing percutaneous revascularization: a meta-analysis of 11 randomized trials. Int J Cardiol 2018;264:30–38. https://doi.org/10.1016/j.ijcard.2018.02.095. PMID: 29776573.